Product Information
CARBIDOPA-LEVO ER 25-100 TAB is a generic product labeled by Mylan Institutional LLC, priced at $0.1101 per EA under NDC 51079097820. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Sep 30, 1999. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 100 mg/1; mg/1
Manufacturer
Mylan Institutional LLCNDC
51079097820
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA075091FDA Approved
9/30/1999
TE Code
AB
On Market Since
2/1/2002
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 25-100 TAB has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 59.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1101 per EA |
|---|---|
| All-time high | $0.3892 (May 13, 2015) |
| All-time low | $0.1048 (Nov 20, 2024) |
| 52-week high | $0.1260 |
| 52-week low | $0.1101 |
| Median price | $0.2437 |
| Average price | $0.2320 |
| Largest weekly change | +35.9% (Jan 17, 2018) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 34% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Institutional LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
carbidopa and levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 25-100 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 25-100 TAB, manufactured by Mylan Institutional LLC, is $0.1101 per EA (NDC 51079097820), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVO ER 25-100 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 25-100 TAB has declined 59.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 25-100 TAB?
Since Nov 28, 2013, the NADAC for CARBIDOPA-LEVO ER 25-100 TAB has ranged from a low of $0.1048 (Nov 20, 2024) to a high of $0.3892 (May 13, 2015), with a median of $0.2437 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 25-100 TAB?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVODOPA 25-100 TAB, is $0.0724 per EA — about 34% below CARBIDOPA-LEVO ER 25-100 TAB.
Who manufactures CARBIDOPA-LEVO ER 25-100 TAB?
CARBIDOPA-LEVO ER 25-100 TAB (NDC 51079097820) is labeled by Mylan Institutional LLC, and CMS classifies it as a generic product.